Measurement of the serum level of Leucine-rich alpha-2-glycoprotein-1 in hospitalized Iraqi COVID-19 Patients

Abstract

Objective: The study aimed to assess Leucine-rich alpha-2-glycoprotein-1 biomarker serum level in hospitalized COVID-19 patients.

Methods: The case control study from multi-centers in Baghdad included 45 adult patients (19 females and 26 males) with COVID-19, diagnosed with a positive real-time reverse transcription polymerase chain reaction and excluded negative RT-PCR for COVID-19 and comorbidity conditions. Second group, was 43 control (20 females and 23 males).

Results: This study found a decrease Leucine-rich alpha-2-glycoprotein-1 biomarker serum level in these patients and a significant difference in D. dimer, neutrophil count, lymphocyte count, and the neutrophil-lymphocyte ratio between the patients and controls at a P value equal to 0.000,

Conclusion: The concentration of leucine-rich alpha2 glycoprotien1 in the patients after taking Tocilizumab was greatly decreased in many studies. Most of the patients in the study were treated with Tocilizumab, which directly blocks the effect of IL-6 by blocking the IL-6 receptors and greatly decreased the expression of LRG1 to impair the production of the angiopathogenic constituent.